HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G Stretches ZzzQuil Sleep Brand Into Supplement Space With PureZzzs

This article was originally published in The Pink Sheet

Executive Summary

P&G will launch Vicks ZzzQuil PureZzzs in late February as a drug-free, melatonin-based sleep aid, CFO Jon Moeller says. P&G hopes to reach $4.5bn in e-commerce sales in 2018, up from $3bn in 2017.

You may also be interested in...



Beauty Supplements Draw Young Adults, Disease Prevention Attracts All Ages

Most US women ages 18-34 who take a supplement do so for beauty benefits, finds Mintel in a survey. Natural Marketing Institute says with science increasing understanding of nutrients, firms should offer supplements that address symptoms of common conditions consumers are treating with drugs.

P&G Goes Native In Acquisition That Aligns With Peltz' Vision

P&G's purchase of Native deodorants likely is approved by activist investor and potential board member Nelson Peltz, who has pushed the firm to invest in small and local brands as well as natural products. Analysts believe more tuck-in deals could be in the offing to help the firm compete against rising e-commerce startups.

P&G Board Seat Swings To Peltz In Ongoing Vote Tally

P&G says results from an independent tabulator indicate Trian Fund head Nelson Peltz is leading the firm's candidate, Ernesto Zedillo, in a board proxy vote by around 42,780 shares, or 0.0016% of total outstanding shares. But P&G says the vote count isn't completed.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS122705

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel